This is a PDF copy of the letter June 13, 2025 Robert F. Kennedy, Jr. Secretary U.S. Department of Health and Human Services 200 Independence Ave SW, Washington, DC 20201 RE: Request for issuance of authorization and consent to use… Continue Reading
Letter from KEI, UACT and UAEM to Chiquita White Brooks-Lasure, Administrator of the Office of the Administrator, Centers for Medicare and Medicaid Services, at HHS, asking that CMS to provide a Bayh-Dole Section 202 license and a 28 USC 1498… Continue Reading
On December 19, 2023, three prostate cancer patients, Robert Sachs, Clare Love and Eric Sawyer, sent a letter to Secretary Becerra asking that he act on their appeal of the rejection of their petition, asking the federal government to use… Continue Reading
The U.S. Federal Trade Commission (FTC) mission “is protecting the public from deceptive or unfair business practices and from unfair methods of competition through law enforcement, advocacy, research, and education.” https://www.ftc.gov/about-ftc/mission The advocacy role of the FTC includes to “Advance… Continue Reading
Today, eight non-governmental organizations sent the Biden Administration a letter of support for the administrative appeal of the request for the Department of Health and Human Services (HHS) to use its rights in the patents on the prostate cancer drug… Continue Reading
(UPDATE: A recording of the event is available on our YouTube channel here: https://www.youtube.com/watch?v=_qFgm-dohuU) Date: Thursday April 20, 2023 Time: 1:30 PM to 3:00 PM EDT Knowledge Ecology International is hosting an online discussion of two Bayh-Dole safeguard related topics.… Continue Reading
On March 23, 2023, three prostate cancer patients, Robert Sachs, Clare Love and Eric Sawyer, filed an administrative appeal of the NIH decision to reject petition that HHS use Federal rights in patents on Xtandi to address pricing discrimination against… Continue Reading
On January 10, 2023, twenty-five Members of Congress sent a letter to HHS Secretary Xavier Becerra urging him to act on the Xtandi request, and to use the Bayh-Dole Act to lower the price of Xtandi (enzalutamide) for US patients.… Continue Reading
NIH has sent a letter, dated Dec 1, to Robert Sachs and Clare Love, regarding the longstanding petition to HHS to use the federal government’s rights in the patented inventions for enzalutamide, marketed by Astellas in the USA at prices 3 to… Continue Reading